Inhibitor of streptokinase gene expression improves survival after group A streptococcus infection in mice

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Antibiotic resistance in human pathogens is a significant global health concern.
• Conventional antibiotics promote resistance by targeting bacterial killing or growth inhibition.
• Alternative strategies targeting pathogenicity without inhibiting growth could mitigate resistance selection.

Purpose of the Study:

• To identify small molecules that inhibit the virulence factor streptokinase (SK) in Group A Streptococcus (GAS).
• To evaluate the therapeutic potential of identified compounds against GAS infections.
• To explore novel antimicrobial approaches that minimize resistance development.

Main Methods:

• High-throughput screening of 55,000 small molecules to identify inhibitors of streptokinase gene expression.
• Confirmation of lead compounds' ability to inhibit active SK protein production.
• Microarray analysis to assess global gene expression changes in GAS.
• In vitro assays measuring granulocyte phagocytosis and killing of GAS.
• In vivo studies evaluating protection against GAS-induced mortality in mice.

Main Results:

• Identification of CCG-2979 as a lead compound inhibiting SK gene expression and protein production.
• CCG-102487, an analog, also inhibited SK and down-regulated other GAS virulence factors, suggesting disruption of a regulatory network.
• Both compounds enhanced phagocytosis and killing of GAS by granulocytes in vitro.
• CCG-2979 demonstrated protective effects against GAS-induced mortality in a mouse model in vivo.

Conclusions:

• Compounds like CCG-2979 represent a promising class of therapeutics for treating GAS infections.
• This approach targets virulence rather than bacterial growth, potentially reducing the selection pressure for antibiotic resistance.
• Further investigation into this compound class may yield treatments for other Gram-positive bacterial infections.